Drug intelligence / Profile preview

Hejie Zhitong prescription

Development stage: Preclinical

Overview

Hejie Zhitong prescription (HJZT) is a traditional medicine formulation that has been utilized clinically for many years in the treatment of migraine. Research indicates that HJZT promotes sleep and inhibits nociceptive transmission-associated neurotransmitter activity, which are key mechanisms in its antimigraine effects. Its mechanism involves modulating neurotransmitters related to pain transmission and demonstrating a synergistic effect with pentobarbital sodium on promoting sleep.

Targets

CCKAR (Cholecystokinin A receptor)CNR1 (Cannabinoid receptor 1)Calcitonin gene-related peptide type 1 receptorPTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Hejie Zhitong prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hejie Zhitong prescription.

Explore the full profile